Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

LL-2113AD shows promise as add-on therapy for type 2 diabetes

Jan. 31, 2005

Merck presents new DPP-IV inhibitors with potential use in diabetes

Jan. 28, 2005

New clinical data on estrogen therapy and the risk of gallbladder disease in postmenopausal women

Jan. 28, 2005

E1-I.N.T. cleared to enter clinical trials for type 2 diabetes

Jan. 28, 2005

New phase I study for PYY3-36 Nasal Spray for obesity

Jan. 28, 2005

Nektar and Zelos Therapeutics collaborate on inhaleable Ostabolin-C

Jan. 28, 2005

Bound follicle-stimulating hormone crystal structure determined

Jan. 27, 2005

Biovitrum discloses 11beta-HSD1 inhibitors for diabetes, obesity, etc.

Jan. 27, 2005

K-11706 shows promise in orally treating ACD

Jan. 27, 2005

Insulin sensitizers described in a patent

Jan. 26, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....